E
Erich Jaeger
Researcher at University of California, San Francisco
Publications - 7
Citations - 1049
Erich Jaeger is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Clear cell renal cell carcinoma & Cancer. The author has an hindex of 6, co-authored 7 publications receiving 971 citations.
Papers
More filters
Journal ArticleDOI
Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
Michael L. Nickerson,Erich Jaeger,Yangu Shi,Jeffrey A. Durocher,Sunil Mahurkar,David Zaridze,Vsevolod Matveev,Vladimir Janout,H. Kollarova,Vladimir Bencko,Marie Navratilova,Neonilia Szeszenia-Dabrowska,Dana Mates,Anush Mukeria,Ivana Holcatova,Laura S. Schmidt,Jorge R. Toro,Sara Karami,Rayjean J. Hung,Rayjean J. Hung,Gary F. Gerard,W. Marston Linehan,Maria J. Merino,Berton Zbar,Paolo Boffetta,Paul Brennan,Nathaniel Rothman,Wong Ho Chow,Frederic M. Waldman,Lee E. Moore +29 more
TL;DR: Analysis of patient and tumor characteristics revealed that certain mutation subtypes were significantly associated with Fuhrman nuclear grade, metastasis, node positivity, and self-reported family history of RCC, indicating that VHL molecular subtypes can provide a sensitive marker of tumor heterogeneity among histologically similar ccRCC cases for etiologic, prognostic, and translational studies.
Journal ArticleDOI
von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
Toni K. Choueiri,Susan A.J. Vaziri,Erich Jaeger,Paul Elson,Laura S. Wood,Ish Prasad Bhalla,Eric J. Small,Vivian Weinberg,Nancy Sein,Jeff Simko,Ali Reza Golshayan,Linda Sercia,Ming Zhou,Frederic M. Waldman,Brian I. Rini,Ronald M. Bukowski,Ram Ganapathi +16 more
TL;DR: This is the largest analysis investigating the impact of VHL inactivation on the outcome of vascular endothelial growth factor targeted agents in metastatic renal cell carcinoma and did not find a statistically significant increase in response.
Journal ArticleDOI
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Lee E. Moore,Michael L. Nickerson,Paul Brennan,Jorge R. Toro,Erich Jaeger,Jessica Rinsky,Summer S. Han,David Zaridze,Vsevolod Matveev,Vladimir Janout,H. Kollarova,Vladimir Bencko,Marie Navratilova,Neonilia Szeszenia-Dabrowska,Dana Mates,Laura S. Schmidt,Laura S. Schmidt,Petra Lenz,Sara Karami,W. Marston Linehan,Maria J. Merino,Stephen J. Chanock,Paolo Boffetta,Paolo Boffetta,Wong Ho Chow,Frederic M. Waldman,Nathaniel Rothman +26 more
TL;DR: In this article, a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL-inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs) was provided.
Journal ArticleDOI
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status
Brian I. Rini,Erich Jaeger,Vivian Weinberg,Nancy Sein,Karen Chew,Kristen Fong,Jeffery Simko,Eric J. Small,Frederic M. Waldman +8 more
TL;DR: To describe the relationship among patient characteristics, Von Hippel‐Lindau (VHL) gene status and clinical outcome in metastatic renal cell carcinoma (RCC) in patients receiving vascular endothelial growth factor (VEGF)‐targeted therapy is described.
Journal ArticleDOI
Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.
Lee E. Moore,Erich Jaeger,Michael L. Nickerson,Paul Brennan,S. De Vries,Ritu Roy,Jorge R. Toro,H. Li,Sara Karami,Petra Lenz,David Zaridze,Vladimir Janout,Vladimir Bencko,Marie Navratilova,Neonilia Szeszenia-Dabrowska,Dana Mates,W. M. Linehan,Maria J. Merino,Jeffry P. Simko,Ruth M. Pfeiffer,Paolo Boffetta,Stephen M. Hewitt,Nathanial Rothman,Wong-Ho Chow,F. M. Waldman +24 more
TL;DR: Patients characterized by VHL wild-type gene status (vs sequence alterations) and male (vs female) cases had more copy number alterations regardless of diagnostic stage and grade, which could relate to poor prognosis.